Giuseppina Roscigno

Giuseppina Roscigno

Auto-generated profile, based on publicly available information

Giuseppina Roscigno

Department of Molecular Medicine and Medical Biotechnology, “Federico II” University of Naples, Via Pansini 5, 80131 Naples, Italy

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
EDElvira Donnarumma
Elvira Donnarumma
DFDanilo Fiore
Danilo Fiore
MNMartina Nappa
Martina Nappa
GRGiuseppina Roscigno
Giuseppina Roscigno
AAAssunta Adamo
Assunta Adamo
Gerolama CondorelliGerolama Condorelli
Gerolama Condorelli
Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer

Verified
Journal Article
Open access
PDF file
FIFrancesco Ingenito
Francesco Ingenito
GRGiuseppina Roscigno
Giuseppina Roscigno
AAAlessandra Affinito
Alessandra Affinito
SNSilvia Nuzzo
Silvia Nuzzo
ISIolanda Scognamiglio
Iolanda Scognamiglio
Gerolama CondorelliGerolama Condorelli
Gerolama Condorelli
Exosomes are extracellular vesicles released into biological fluids where they act as carriers of various molecules, including proteins, lipids, and RNAs, between cells, modulating or perturbing specific physiological processes. Recently, it has been suggested that tumoral cells release excessive amounts of exosomes that, through their cargo, promote tumor progression, stimulating growth, angiogenesis, metastasis, insensitivity to chemotherapy, and immune evasion. Increasing evidence highlights exosomal microRNAs (exo-miRNAs) as important players in tumorigenesis. MicroRNA (miRNA) are a class of small non-coding RNA able to regulate gene expression, targeting multiple mRNAs and inducing translational repression and/or mRNA degradation. Exo-miRNAs are highly stable and easily detectable in biological fluids, and for these reasons, miRNAs are potential cancer biomarkers useful diagnostically and prognostically. Furthermore, since exosomes are natural delivery systems between cells, they can be appropriately modified to carry therapeutic miRNAs to specific recipient cells. Here we summarize the main functions of exo-miRNAs and their possible role for diagnostic and therapeutic applications.

10 September 2012 in Oncogene
Verified
Journal Article
Closed access
CQC Quintavalle
C Quintavalle
EDE Donnarumma
E Donnarumma
MIM Iaboni
M Iaboni
GRG Roscigno
G Roscigno
MGM Garofalo
M Garofalo
Gerolama CondorelliGerolama Condorelli
Gerolama Condorelli

19 September 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CQCristina Quintavalle
Cristina Quintavalle
DMDavide Mangani
Davide Mangani
GRGiuseppina Roscigno
Giuseppina Roscigno
GRGiulia Romano
Giulia Romano
ADAngel Diaz-Lagares
Angel Diaz-Lagares
Gerolama CondorelliGerolama Condorelli
Gerolama Condorelli
Glioblastoma multiforme (GBM) is one of the most deadly types of cancer. To date, the best clinical approach for treatment is based on administration of temozolomide (TMZ) in combination with radiotherapy. Much evidence suggests that the intracellular level of the alkylating enzyme O6-methylguanine–DNA methyltransferase (MGMT) impacts response to TMZ in GBM patients. MGMT expression is regulated by the methylation of its promoter. However, evidence indicates that this is not the only regulatory mechanism present. Here, we describe a hitherto unknown microRNA-mediated mechanism of MGMT expression regulation. We show that miR-221 and miR-222 are upregulated in GMB patients and that these paralogues target MGMT mRNA, inducing greater TMZ-mediated cell death. However, miR-221/miR-222 also increase DNA damage and, thus, chromosomal rearrangements. Indeed, miR-221 overexpression in glioma cells led to an increase in markers of DNA damage, an effect rescued by re-expression of MGMT. Thus, chronic miR-221/222-mediated MGMT downregulation may render cells unable to repair genetic damage. This, associated also to miR-221/222 oncogenic potential, may poor GBM prognosis.

19 October 2015 in Oncotarget
Verified
Journal Article
Open access
GRGiuseppina Roscigno
Giuseppina Roscigno
CQCristina Quintavalle
Cristina Quintavalle
EDElvira Donnarumma
Elvira Donnarumma
IPIlaria Puoti
Ilaria Puoti
ADAngel Diaz-Lagares
Angel Diaz-Lagares
Gerolama CondorelliGerolama Condorelli
Gerolama Condorelli
MiR-221 promotes stemness of breast cancer cells by targeting DNMT3b

1 May 2018 in Annals of Oncology
Verified
Journal Article
Closed access
CNCharlotte K Y Ng
Charlotte K Y Ng
GCG.G. Di Costanzo
G.G. Di Costanzo
NTN. Tosti
N. Tosti
VPV. Paradiso
V. Paradiso
MCM. Coto-Llerena
M. Coto-Llerena
Salvatore PiscuoglioSalvatore Piscuoglio
Salvatore Piscuoglio
Hepatocellular carcinomas (HCCs) are not routinely biopsied, resulting in a lack of tumor materials for molecular profiling. Here we sought to determine whether plasma-derived cell-free DNA (cfDNA) captures the genetic alterations of HCC in patients who have not undergone systemic therapy. Frozen biopsies from the primary tumor and plasma were synchronously collected from 30 prospectively recruited, systemic treatment-naïve HCC patients. Deep sequencing of the DNA from the biopsies, plasma-derived cfDNA and matched germline was carried out using a panel targeting 46 coding and non-coding genes frequently altered in HCCs. In 26/30 patients, at least one somatic mutation was detected in biopsy and/or cfDNA. Somatic mutations in HCC-associated genes were present in the cfDNA of 63% (19/30) of the patients and could be detected 'de novo' without prior knowledge of the mutations present in the biopsy in 27% (8/30) of the patients. Mutational load and the variant allele fraction of the mutations detected in the cfDNA positively correlated with tumor size and Edmondson grade. Crucially, among the seven patients in whom the largest tumor was ≥5 cm or was associated with metastasis, at least one mutation was detected 'de novo' in the cfDNA of 86% (6/7) of the cases. In these patients, cfDNA and tumor DNA captured 87% (80/92) and 95% (87/92) of the mutations, suggesting that cfDNA and tumor DNA captured similar proportions of somatic mutations. In patients with high disease burden, the use of cfDNA for genetic profiling when biopsy is unavailable may be feasible. Our results support further investigations into the clinical utility of cfDNA in a larger cohort of patients.